Clinical trial · no report yet · Phase 3
DESTINY-Lung04
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
- NCT05048797 ↗
- Active, not recruiting
- AstraZeneca
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 47 | |
| Podcasts | 31 | |
| YouTube | 29 | |
| X videos | 2 |
The trial
ClinicalTrials.gov- Official title
- An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Interventions
- Trastuzumab Deruxtecan; Cisplatin; Carboplatin; Pembrolizumab; Pemetrexed
- Arms
- Arm 1 · Experimental
- Arm 2 · Active comparator
- Enrollment
- 454
- Primary outcomes
- Progression Free Survival (PFS) by Blinded Independent Central Review (BICR)
- Sponsor
- AstraZeneca with Daiichi Sankyo
- Start
- Oct 28, 2021
- Primary completion
- Jun 9, 2026
- Results posted
- No
- Registry record
- NCT05048797 · updated Jul 10, 2026